Genesis: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.trygenesis.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.

1. 1

   “The compounded semaglutide and tirzepatide products displayed on your website identify “Genesis” on the pictured label, suggesting Genesis is the compounder of those drugs when in fact it is not.”

2. 2

   “Additionally, the following claims concerning compounded semaglutide and tirzepatide products appear on your website: “Contains the same active ingredient as Ozempic® and Wegovy®” “Same active ingredient as Mounjaro®””

3. 3

   “Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”

1. 1

   Letter issued

   February 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

trygenesis.com returned a live storefront on 2026-08-09, titled "Genesis Health | Lose Weight with Proven GLP-1 Medications Personalized Tirzepatide & Semaglutide doses", with published monthly prices and the same Boynton Beach corporate details the letter gives.

The private-label finding is the one that changes how you read a price. A vial with the seller's own name on it invites you to think you are buying from them — that they made it, that the price is their cost plus their margin, that quality questions have one address. FDA says the seller is not the compounder. So the name on the label is branding applied to someone else's product, and the actual manufacturer is not disclosed to you at the point where you are deciding what the medicine is worth. That is not a safety finding and it is not unusual in this market; nearly every letter in this collection contains the same observation. What it means practically is that two sellers at very different prices can be shipping vials from the same facility with different names printed on them, and nothing on either page will tell you.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Genesis failed to respond.